JP2016106149A5 - - Google Patents

Download PDF

Info

Publication number
JP2016106149A5
JP2016106149A5 JP2016051146A JP2016051146A JP2016106149A5 JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5 JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
hepatitis
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016051146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016106149A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016106149A publication Critical patent/JP2016106149A/ja
Publication of JP2016106149A5 publication Critical patent/JP2016106149A5/ja
Pending legal-status Critical Current

Links

JP2016051146A 2010-11-17 2016-03-15 抗ウイルス化合物 Pending JP2016106149A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41481810P 2010-11-17 2010-11-17
US61/414,818 2010-11-17
US201161504924P 2011-07-06 2011-07-06
US61/504,924 2011-07-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013539970A Division JP5905020B2 (ja) 2010-11-17 2011-11-16 抗ウイルス化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017240524A Division JP2018039851A (ja) 2010-11-17 2017-12-15 抗ウイルス化合物

Publications (2)

Publication Number Publication Date
JP2016106149A JP2016106149A (ja) 2016-06-16
JP2016106149A5 true JP2016106149A5 (en:Method) 2016-10-20

Family

ID=45099196

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013539970A Active JP5905020B2 (ja) 2010-11-17 2011-11-16 抗ウイルス化合物
JP2016051146A Pending JP2016106149A (ja) 2010-11-17 2016-03-15 抗ウイルス化合物
JP2017240524A Withdrawn JP2018039851A (ja) 2010-11-17 2017-12-15 抗ウイルス化合物
JP2019206819A Withdrawn JP2020037584A (ja) 2010-11-17 2019-11-15 抗ウイルス化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013539970A Active JP5905020B2 (ja) 2010-11-17 2011-11-16 抗ウイルス化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017240524A Withdrawn JP2018039851A (ja) 2010-11-17 2017-12-15 抗ウイルス化合物
JP2019206819A Withdrawn JP2020037584A (ja) 2010-11-17 2019-11-15 抗ウイルス化合物

Country Status (18)

Country Link
US (3) US9156823B2 (en:Method)
EP (3) EP3699176A3 (en:Method)
JP (4) JP5905020B2 (en:Method)
KR (5) KR20200140924A (en:Method)
AR (1) AR083711A1 (en:Method)
AU (3) AU2011328980B2 (en:Method)
CA (3) CA3095528C (en:Method)
ES (1) ES2634095T3 (en:Method)
HK (1) HK1250162A1 (en:Method)
IL (1) IL226346A (en:Method)
NZ (2) NZ726475A (en:Method)
PL (1) PL2640719T3 (en:Method)
PT (1) PT2640719T (en:Method)
SG (2) SG10201509456SA (en:Method)
SI (1) SI2640719T1 (en:Method)
TW (3) TWI548629B (en:Method)
UY (1) UY33735A (en:Method)
WO (1) WO2012068234A2 (en:Method)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
SI3309157T1 (sl) 2009-05-13 2020-02-28 Gilead Pharmasset Llc Protivirusne spojine
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI402070B (zh) 2009-06-11 2013-07-21 Abbott Lab 抗病毒化合物
CA2800530A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
TWI548629B (zh) 2010-11-17 2016-09-11 吉李德製藥公司 抗病毒化合物
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013040492A2 (en) 2011-09-16 2013-03-21 Gilead Sciences, Inc. Methods for treating hcv
AU2015252077A1 (en) * 2011-11-16 2015-11-19 Gilead Pharmasset Llc Antiviral compounds
DK2907816T3 (en) * 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) * 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014122895A1 (ja) * 2013-02-07 2014-08-14 保土谷化学工業株式会社 ジアザトリフェニレン環構造を有する化合物および有機エレクトロルミネッセンス素子
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20140343008A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatment
CN104211677B (zh) * 2013-05-30 2018-02-23 浙江九洲药业股份有限公司 一种抗丙型肝炎药物中间体的制备方法
CN104211565A (zh) * 2013-05-31 2014-12-17 浙江九洲药业股份有限公司 一种抗丙型肝炎药物中间体的制备方法
EA201592167A1 (ru) 2013-06-26 2016-05-31 Чжэцзян Цзючжоу Фармасьютикал Ко., Лтд. Способ получения производных пирролидин-2-карбоновой кислоты
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
NZ716840A (en) * 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015030854A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
WO2015089810A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015101215A1 (zh) * 2013-12-31 2015-07-09 南京圣和药业股份有限公司 9,9,10,10-四氟-9,10二氢菲类丙型肝炎病毒抑制剂及其应用
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CA2951147A1 (en) * 2014-06-12 2015-12-17 Gilead Sciences, Inc. Antiviral compounds
CA2972259A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN104592124B (zh) * 2015-01-04 2018-01-02 华南理工大学 一种萘[1,2]并咪唑双极性共轭化合物及制备与应用
TWI703141B (zh) * 2015-03-12 2020-09-01 大陸商廣東東陽光藥業有限公司 作為丙型肝炎抑制劑的化合物及其在藥物中的應用
WO2016202232A1 (zh) * 2015-06-19 2016-12-22 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法
CN106256819B (zh) * 2015-06-19 2019-07-09 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101919194B1 (ko) * 2015-09-15 2018-11-15 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2017181383A1 (en) * 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
SG11201809893WA (en) 2016-05-27 2018-12-28 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
CN106432197B (zh) * 2016-09-07 2019-12-10 上海众强药业有限公司 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
CN107573355B (zh) * 2016-11-30 2020-03-17 上海博志研新药物技术有限公司 维帕他韦、其中间体及制备方法
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
MX2020005392A (es) 2017-12-07 2020-12-07 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
KR102586510B1 (ko) 2018-02-13 2023-10-12 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US20210267932A1 (en) 2018-05-15 2021-09-02 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods of using, and methods for preparing compounds
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
KR102316919B1 (ko) 2019-11-28 2021-10-22 서울시립대학교 산학협력단 피지컬 컴퓨팅 소프트웨어를 이용한 코딩 교육 교재 및 이를 활용한 코딩 교육 방법
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN112877379B (zh) * 2021-01-18 2023-09-01 华南理工大学 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法
CA3219397A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
CA3220903A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
ES2456702T3 (es) 2003-05-09 2014-04-23 Boehringer Ingelheim International Gmbh Bolsillo de unión del inhibidor de la polimerasa NS5B del virus de la hepatitis C
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
US7642339B2 (en) 2004-07-16 2010-01-05 Gilead Sciences, Inc. Antiviral compounds
WO2006089231A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2823981C (en) 2006-12-07 2016-05-17 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
DK2242752T3 (da) * 2008-02-13 2012-11-19 Bristol Myers Squibb Co Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010062821A1 (en) * 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010065681A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG174146A1 (en) 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
CA2756255A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
AU2010229795A1 (en) 2009-03-27 2011-10-13 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
SI3309157T1 (sl) * 2009-05-13 2020-02-28 Gilead Pharmasset Llc Protivirusne spojine
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5795316B2 (ja) 2009-09-04 2015-10-14 ヤンセン ファーマシューティカルズ,インコーポレーテッド 化合物
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2782024A1 (en) * 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104341401B (zh) 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EA201290882A1 (ru) * 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
US9125904B1 (en) * 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
TWI548629B (zh) 2010-11-17 2016-09-11 吉李德製藥公司 抗病毒化合物
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
DK2907816T3 (en) 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Similar Documents

Publication Publication Date Title
JP2016106149A5 (en:Method)
JP2017186358A5 (en:Method)
JP2014507446A5 (en:Method)
JP2018024670A5 (en:Method)
JP2017105793A5 (en:Method)
HRP20230274T1 (hr) Kemijski spojevi
JP2016034978A5 (en:Method)
JP2021502388A5 (en:Method)
JP2019524883A5 (en:Method)
JP2020097577A5 (en:Method)
JP2015078230A5 (en:Method)
JP2014156468A5 (en:Method)
JP2018048154A5 (en:Method)
JP2012532874A5 (en:Method)
JP2016514159A5 (en:Method)
JP2016522254A5 (en:Method)
JP2016539157A5 (en:Method)
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
JP2016510326A5 (en:Method)
JP2016540015A5 (en:Method)
JP2015516419A5 (en:Method)
JP2016523260A5 (en:Method)
JP2018501215A5 (en:Method)
JP2017522300A5 (en:Method)
HRP20191121T1 (hr) Tretman multiple skleroze